Pharmaceutical formulation and process
AssigneeNeXstar Pharmaceuticals, Inc.
InventorsJill P. Adler-Moore, William A. Ernst
Life of this patent
Estimating the term…
Abstract
A process for preparing a liposomal cyclosporin therapeutic formulation, which comprises dissolving a combination of a neutral and negatively charged phospholipid and a cyclosporin in an organic solvent; drying the solution to form a solid phase, and hydrating the solid phase in an aqueous solution having a pH ranging from 7.5 to 9.5.
Claims8
Therapeutic liposomes comprising (i) a neutral lipid, (ii) a negatively charged lipid selected from the group consisting of dimyristoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, dilauryl phosphatidylglycerol, and dimyristoyl phosphatidic acid, and (iii) a cyclosporin, where the liposomes have a mean diameter of less than 200 nm and are stable on storage.
Therapeutic liposomes comprising (i) a neutral lipid, (ii) a negatively charged lipid selected from the group consisting of dimyristoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, dilauryl phosphatidylglycerol, and dimyristoyl phosphatidic acid, and (iii) cholesterol in amounts up to 50 mole percent of the neutral lipid, and (iv) a cyclosporin, where the liposomes have a mean diameter of less than 200 nm and are stable on storage.
Dependencies are inferred from the claim text.